|
Degenerative polyarthritis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Genes with decreased expression in OA were MMP1, MMP3, and ADAMTS1 (all at P < 0.001), MMP10, TIMP1, and ADAMTS9 (all at P < 0.01), and TIMP4, ADAMTS5, and ADAMTS15 (all at P < 0.05).
|
14730609 |
2004 |
|
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.
|
15599946 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, this study identifies and provides functional evidence for a CR associated with tumor suppression on 3p14.2 and provides the first evidence that ADAMTS9, mapping to this region, may contribute to esophageal cancer development.
|
16799631 |
2007 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Downregulation of ADAMTS9 was also found in 43.5 and 47.6% of primary esophageal tumor tissues from Hong Kong and from the high-risk region of Henan, respectively.
|
16799631 |
2007 |
|
Esophageal Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Downregulation of ADAMTS9 was also found in 43.5 and 47.6% of primary esophageal tumor tissues from Hong Kong and from the high-risk region of Henan, respectively.
|
16799631 |
2007 |
|
Esophageal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Complete loss or downregulation of ADAMTS9 gene expression was found in 15 out of 16 esophageal carcinoma cell lines.
|
16799631 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
CTD_human |
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.
|
18372903 |
2008 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the impact on diabetes-related intermediary traits of common novel type 2 diabetes-associated variants in the JAZF1 (rs864745), CDC123/CAMK1D (rs12779790), TSPAN8 (rs7961581), THADA (rs7578597), ADAMTS9 (rs4607103), and NOTCH2 (rs10923931) loci, which were recently identified by meta-analysis of genome-wide association data.
|
18567820 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ADAMTS9 expression was downregulated or lost in 17 of 23 (73.9%) lymph node metastatic NPC specimens, which was significantly higher than in 14 of 43 (32.6%) primary tumors.
|
18449890 |
2008 |
|
Nasopharyngeal carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
After transfection of the ADAMTS9 gene into 7 NPC cell lines, a dramatic reduction of colony forming ability was observed.
|
18449890 |
2008 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma.
|
18449890 |
2008 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
BEFREE |
Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients--EUGENE2 study.
|
19789630 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The combined microarray technologies suggested novel candidate oncogenes, amplification of GPR160 and SKIL at 3q26.2-q26.32, and deletion of tumor suppressor genes ADAMTS9 and LRIG1 at 3p12.3-p14.2.
|
19815638 |
2009 |
|
Diabetes
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Assuming an additive genetic model the diabetes-associated major C-allele of rs4607103 near ADAMTS9 associated with reduced insulin-stimulated glucose uptake (p = 0.002) during a hyperinsulinemic euglycemic clamp.
|
19789630 |
2009 |
|
Diabetes Mellitus
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Assuming an additive genetic model the diabetes-associated major C-allele of rs4607103 near ADAMTS9 associated with reduced insulin-stimulated glucose uptake (p = 0.002) during a hyperinsulinemic euglycemic clamp.
|
19789630 |
2009 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
BEFREE |
Several genetic loci (JAZF1, CDC123/CAMK1D, TSPAN8/LGR5, ADAMTS9, VEGFA and HHEX-IDE) were identified to be significantly related to the risk of type 2 diabetes and quantitative metabolic traits in European populations.
|
20927120 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, when congenic with the C57Bl/6 strain, 80% of ADAMTS9+/- mice developed spontaneous corneal neovascularization. beta-Galactosidase staining enabled by a lacZ cassette targeted to the ADAMTS9 locus showed that capillary endothelial cells (ECs) in embryonic and adult tissues and in capillaries growing into heterotopic tumors expressed ADAMTS9.
|
20093484 |
2010 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The present study is novel in evaluating the prevalence of ADAMTS9 methylation based on a large number of tumor samples and showing that epigenetic regulation of ADAMTS9 was associated with carcinogenesis.
|
19963134 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results indicate that ADAMTS9 contributes an important function in the tumor microenvironment that acts to inhibit angiogenesis and tumor growth in both ESCC and NPC.
|
20551050 |
2010 |
|
Nasopharyngeal carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The ADAMTS9 gene (ADAM metallopeptidase with thrombospondin type 1 motif, 9); has been characterized as a novel tumor suppressor gene in and epigenetically silenced in association with lymph node metastases in nasopharyngeal carcinoma.
|
19963134 |
2010 |
|
Nasopharyngeal carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The metalloprotease ADAMTS9 participates in melanoblast development and is a tumor suppressor in esophageal and nasopharyngeal cancer.
|
20093484 |
2010 |
|
Nasopharyngeal carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that ADAMTS9 contributes an important function in the tumor microenvironment that acts to inhibit angiogenesis and tumor growth in both ESCC and NPC.
|
20551050 |
2010 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
However, the functional impact of ADAMTS9 on cancer development has not been explored.
|
20551050 |
2010 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
However, the functional impact of ADAMTS9 on cancer development has not been explored.
|
20551050 |
2010 |
|
Malignant neoplasm of stomach
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we report HRM analysis used to detect the methylation levels of ADAMTS9 gene in 100 gastric cancers, 100 colorectal cancers, 70 pancreatic cancers, and an equal number of adjacent normal tissues.
|
19963134 |
2010 |